1. MARKETS
  2. SECTOR : HEALTHCARE
  3. INDUSTRY : HEALTHCARE SERVICES
  4. DR. LAL PATHLABS LTD.
Dr. Lal Pathlabs Ltd.
NSE: LALPATHLAB | BSE: 539524

Dr. Lal Pathlabs Live Share Price Today, Share Analysis and Chart

Expensive Rocket
BasketIn 1 Starfolio Basket
aboutDr. Lal PathLabs Limited is a provider of diagnostic and related healthcare tests and services in India. With a history spanning over 75 years, the company operates an extensive network of laboratories and service centers, providing a comprehensive r... Read More
Revenue per Patient
Ask AI about Dr. Lal Pathlabs
1906.40-5.30(-0.28%)

49.80% Gain from 52W Low

342.4K
NSE+BSE Volume

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Board Meeting
The next board meeting for Dr. Lal Pathlabs is on 04 Nov 2026 for the purpose of Quarterly Results & Interim Dividend See details
Loading...
- / 100
- / 100
60.2 / 100
Expensive RocketThese stocks have good momentum, but are expensive with average financialsView SimilarEmbed DVM
Analyst Price Target
-

21

S

9

W

4

O

2

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

Medium rank

9Positive14Negative

39.1%Pass in checklist

045
55
100

PE Valuation Check

Right Now
Undervalued
6.6%
1 Year Forward
Undervalued
23%
INSIGHTDr. Lal Pathlabs is undervalued at both current PE and future earnings estimates.

Dr. Lal Pathlabs Stock Price Analysis

Day Price Range

-0.3% 1 Day return
1906.4 (LTP)
1,8861,958
LowHigh

Week Price Range

3.7% 1 Week return
1906.4 (LTP)
1,797.81,958
LowHigh

Month Price Range

-4.1% 1 Month return
1906.4 (LTP)
1,797.82,027.6
LowHigh

52 Week Price Range

21.6% 1 Year return
1906.4 (LTP)
1,272.62,038.6
LowHigh
View full Price History/Seasonality

Dr. Lal Pathlabs Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Miss

Dr. Lal Pathlabs's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

CURRENT EPS
30.4
AVG. ESTIMATE
37.1
LOW ESTIMATE
34.5
HIGH ESTIMATE
40.3
CURRENT EPS
AVG. ESTIMATE
Hit

EPS is expected to grow by 21.9% in FY27

Consensus Recommendation

26 ANALYST Recommendations
BUY

The consensus recommendation from 26 analysts for Dr. Lal Pathlabs is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Dr. Lal Pathlabs Technical Analysis

Dr. Lal Pathlabs EMA & SMA

Bullish+8
8 bullish, 0 bearish
Bullish8
Bearish0
5 Day1898.9
10 Day1893.0
12 Day1893.7
20 Day1899.2
26 Day1901.7
50 Day1890.5
100 Day1824
200 Day1717.3

Dr. Lal Pathlabs Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202658.6%
Week70.4%
Month62.9%

Dr. Lal Pathlabs Active Candlesticks

Long Legged Doji Uptrend Rickshaw Man Uptrend
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Dr. Lal Pathlabs Resistance and Support

1916.80
Pivot
First Resistance1947.6
Second Resistance1988.8
Third Resistance2019.6
First Support1875.6
Second Support1844.8
Third Support1803.6
Day RSI50.8
Day MACD-8
Day MFI41
Day MACD Signal Line-10.3

Dr. Lal Pathlabs Beta

1 Month-0.4
1 Year0.4
3 Month-0.3
3 Year0.4

Dr. Lal Pathlabs Price Change Analysis

↓-4.1%
Over 1 Month
LowHigh
1797.82027.6
↑0.1%
Over 3 Months
LowHigh
1797.82038.6
↑39.4%
Over 6 Months
LowHigh
13902038.6
↑21.6%
Over 1 Year
LowHigh
1272.62038.6
All Technicals →

Dr. Lal Pathlabs Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Arvind LalPromoter50,210,88629.9 %
Smallcap World Fund, IncFii4,367,7302.6 %
Hdfc Mutual Fund - Hdfc Nifty Smallcap 250 EtfDii6,559,5903.9 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Dr. Lal Pathlabs Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
GOLDMAN SACHS (SINGAPORE) PTE - ODIBlockSell20 Oct 2025316033,414NSE
GOLDMAN SACHS BANK EUROPE SE - ODIBlockPurchase20 Oct 2025316033,414NSE
MULTI-MANAGER ICVCBulkSell06 Jan 20252997.11434,943NSE
ISHARES INDIA SC MAURITIUS COMPANYBlockSell25 Oct 20222550.9012,949BSE
ISHARES CORE EMERGING MARKETS MAURITIUS COBlockSell25 Oct 20222550.9069,319BSE
ISHARES MSCI INDIA SMALL-CAP ETFBlockPurchase25 Oct 20222550.9012,949BSE
ISHARES CORE MSCI EMERGING MARKETS ETFBlockPurchase25 Oct 20222550.9069,319BSE
ISHARES INDIA SC MAURITIUS COMPANYBlockSell17 Oct 20222377.5012,934BSE
ISHARES CORE EMERGING MARKETS MAURITIUS COBlockSell17 Oct 20222377.5069,250BSE
ISHARES MSCI INDIA SMALL-CAP ETFBlockPurchase17 Oct 20222377.5012,934BSE
All deals
All insider trades

Dr. Lal Pathlabs Corporate Actions

Dr. Lal Pathlabs Dividend history and yield

Dr. Lal Pathlabs dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Dr. Lal Pathlabs dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
130 Jul 2026
5INTERIM30 Jul 2026Equity Share
225 Jun 2026
4FINAL26 Jun 2026Equity Share
305 Feb 2026
3.5INTERIM05 Feb 2026Equity Share
407 Nov 2025
7INTERIM07 Nov 2025Equity Share
506 Aug 2025
6INTERIM06 Aug 2025Equity Share

Dr. Lal Pathlabs Bonus shares

Dr. Lal Pathlabs bonus history along with announcement, record, ex-bonus dates, and bonus ratios.

#Ex-Date
Bonus RatioRecord Date
119 Dec 2025
1:119 Dec 2025

Dr. Lal Pathlabs Board Meetings

Dr. Lal Pathlabs past and upcoming board meetings.

#Ex-Date
PurposeNotes
104 Nov 2026
Quarterly Results & Interim Dividend-
224 Jul 2026
Quarterly Results-
330 Apr 2026
Audited Results & Final Dividend-
430 Jan 2026
Quarterly Results & Interim DividendTo consider other business matters.
531 Oct 2025
Qtr Results, Int.Dividend & Bonus issue-
All Corporate Actions

Dr. Lal Pathlabs Research Reports

Dr. Lal Pathlabs research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
111 Oct 2026Axis Direct23151969.7Buy17.53%-3.21%pdf
223 Sep 2026Emkay
Target
21001961.3Buy7.07%-2.8%pdf
325 Jul 2026ICICI Securities Limited16901759.2Hold-3.93%8.37%pdf
408 Jun 2026Emkay17401575.8Buy10.42%20.98%pdf
530 Apr 2026Emkay17401367.2Buy27.27%39.44%pdf
All Reports of Dr.

Dr. Lal Pathlabs Corporate Filings

Dr. Lal Pathlabs BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
27 Oct 2026
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Attached
PDF
27 Oct 2026
Dr. Lal PathLabs Ltd - 539524 - Update on board meeting
Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve Update on board meeting
PDF
13 Oct 2026
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Acquisition
Attached
PDF
12 Oct 2026
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Acquisition
Attached
PDF
09 Oct 2026
Dr. Lal PathLabs Ltd - 539524 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Attached
PDF
VIEW ALL

Dr. Lal Pathlabs DocumentsAsk MarketMind AI

Dr. Lal Pathlabs Earnings Call

Dr. Lal Pathlabs earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
30 Jul 2026Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
24 Jul 2026Dr. Lal Pathlabs Results Earnings Call for Q1FY27AudioVideo
06 May 2026Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
03 Feb 2026Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
30 Jan 2026Dr. Lal Pathlabs Results Earnings Call for Q3FY26AudioVideo
view all

Dr. Lal Pathlabs Annual Reports

Dr. Lal Pathlabs financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2023Annual Report Mar-2023Link
2022Annual Report Mar-2022Link

Dr. Lal Pathlabs Credit Ratings

Dr. Lal Pathlabs credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
31 Mar 2026care ratingsDr. Lal Pathlabs LimitedLink
21 Apr 2025care ratingsDr. Lal Pathlabs LimitedLink
16 Mar 2025care ratingsDr. Lal Pathlabs LimitedLink
13 Feb 2024care ratingsDr. Lal Pathlabs LimitedLink
07 May 2023crisil ratingsDr. Lal Pathlabs LimitedDr. Lal Pathlabs Limited:Ratings Reaffirmed and WithdrawnLink

Dr. Lal Pathlabs Investor Presentations

Dr. Lal Pathlabs investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
24 Jul 2026Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
30 Apr 2026Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
30 Jan 2026Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
31 Oct 2025Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
31 Jul 2025Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

Dr. Lal Pathlabs - Company Profile

Dr. Lal Pathlabs Management Structure

Dr. Lal Pathlabs management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Mr. Shankha BanerjeeChief Executive Officer-Mar 26
Mr. Ved Prakash GoelChief Financial Officer,Chief Executive Officer(International Business)-Mar 26
Mr. Jai Prakash MeenaChief Operating Officer-Mar 26
Mr. Munender SopernaChief Information & Digital Officer-Mar 26
Mr. Manoj Kumar GargGroup Chief Human Resources Officer-Mar 26
Vinay GujralCompany Secretary,Compliance Officer-Mar 26
Dr. Reena NakraChief Scientific Officer-Mar 26
Dr. Saloni KheraChief Lab Management Officer-Mar 26

Dr. Lal Pathlabs Board of Directors

Dr. Lal Pathlabs Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Arvind LalChairman/ED & CEO402.6Mar 26
Vandana LalWTD & Executive Director322.8Mar 26
Arun DuggalLead Independent Non Executive Director98.5Mar 26
Rohit BhasinIndependent Non Exe. Director64Mar 26
Somya SatsangiIndependent Non Exe. Director57Mar 26
Rahul SharmaNon Executive Director53Mar 26
Gurinder Singh KalraIndependent Non Exe. Director49Mar 26
RAJIT MEHTAIndependent Non Exe. Director49Mar 26
Archana Lal ErdmannNon Executive Director48Mar 26
Vinay GujralCompany Sec. & Compli. Officer-Mar 26

Dr. Lal Pathlabs Brands

Brands owned by Dr. Lal Pathlabs

LOGOBRAND NAME
Dr Lal Pathlabs Ltd
Website: www.lalpathlabs.com

About the company - Business Profile

Dr. Lal PathLabs Limited is a provider of diagnostic and related healthcare tests and services in India. With a history spanning over 75 years, the company operates an extensive network of laboratories and service centers, providing a comprehensive range of pathology and radiology tests to individual patients, hospitals, and other healthcare providers.

Key Points

  • Key Facts: Founded in 1949 by Dr. Major S. K. Lal and incorporated in 1995, the company is headquartered in Delhi. It is listed on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE).
  • Operations and Resources: As of March 31, 2025, the company's network comprises 298 clinical laboratories, including a National Reference Lab in Delhi and Regional Reference Labs in Kolkata, Bangalore, and Mumbai. The infrastructure includes 6,607 Patient Service Centers (PSCs) and 12,365 Pick-up Points (PUPs). The laboratories hold 40 NABL and 2 CAP accreditations.
  • Market and Significance: The company processed approximately 85.6 million samples from 28.8 million patients in FY25. It serves diverse market segments, including individual patients (B2C) and institutional clients like hospitals and corporates (B2B).
  • Business Model: Dr. Lal PathLabs operates on an asset-light, scalable model integrated through a centralized IT platform. It focuses on expanding its geographic reach through a "Hub and Spoke" architecture and driving growth via a mix of organic expansion and strategic acquisitions, such as Suburban Diagnostics in 2021.
  • Financial Performance (FY25):
    • Revenue: ₹24,614 million (10.5% YoY growth).
    • EBITDA: ₹6,956 million (14.2% growth), with a margin of 28.3%.
    • PAT: ₹4,922 million (35.9% growth), with a margin of 20.0%.
    • ROCE: 35% (42.8% excluding cash and investments).
  • Revenue Breakdown:
    • By Segment: B2C accounts for 74% of revenue, while B2B contributes 26%.
    • By Geography: Delhi NCR (31.08%), UP & Uttarakhand (18.62%), Rest of North India (13.20%), West India (14.62%), East India (14.55%), South India (5.62%), and Others (2.31%).
  • Key Offerings and Innovation: The test menu includes 5,012 pathology and radiology tests. Strategic initiatives include the "Swasthfit" bundled test program, which contributed 26% to revenue in Q3 FY26. Digital transformation efforts focus on AI and automation, including being the first lab in India to use AI for prostate and breast cancer reporting.
  • Strategic Initiatives: The company is spearheading investments in the South India ecosystem through its Bengaluru Reference Lab and a network of Hub and Satellite labs. Future outlook focuses on deep transformation to address the rising burden of chronic and lifestyle-related diseases through continuous monitoring and early detection.
  • Subsidiaries: Major subsidiaries include PathLabs Unifiers Private Limited (100%), Suburban Diagnostics (India) Private Limited (100%), Paliwal Medicare Private Limited (80%), and international units in Nepal and Bangladesh.

References

  1. Annual Report Apr 2025
  2. Investor Presentation Jan 2026
  3. Investor Presentation Oct 2025

Dr. Lal Pathlabs FAQ

Dr. Lal Pathlabs today is trading in the red, down by 0.28% at ₹1,906.4.
Dr. Lal Pathlabs is currently trading down 0.28% on an intraday basis. In the past week the stock rose 3.71%. Stock has been up 0.06% in the past quarter and rose 21.6% in the past year. You can view this in the share price history/seasonality section.
Dr. Lal Pathlabs is listed on NSE with the ticker LALPATHLAB and on BSE as 539524. It's currently trading on NSE at a share price of ₹1,906.4 and on BSE with a share price of ₹1,892.9.
The market cap of Dr. Lal Pathlabs is ₹31,998.7 Cr. as of Oct 30, 2026.
Dr. Lal Pathlabs announced a INTERIM dividend of 50% which equals ₹5 in Jul 30, 2026.The last three ex-dates for Dr. Lal Pathlabs were Jun 25, 2026, Feb 05, 2026 and Nov 07, 2025. To view the full dividend history of Dr. Lal Pathlabs click here.
Dr. Lal Pathlabs has never issued stock splits, but it has issued 1 bonus shares since its BSE/NSE listing. The latest announcement for Dr. Lal Pathlabs bonus shares was on Dec 19, 2025 at a ratio of 1:1.
Dr. Lal Pathlabs reported ₹829.6 Cr. in revenue, ₹169.5 Cr. in net profit, and ₹279.4 Cr. in EBITD as of Jul 24, 2026 for Q1 FY26-27.
According to the predictions of 26 analysts, the share price prediction for Dr. Lal Pathlabs is ₹2,018.08 with an upside of 6%.
The PE ratio of Dr. Lal Pathlabs is 59.05 as of Oct 30, 2026.
The PB ratio of Dr. Lal Pathlabs is 11.94 as of Oct 30, 2026.
You can view the latest analyst reports on the Dr. Lal Pathlabs reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×